Point72 Asset Management L.P. Has $680,000 Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Point72 Asset Management L.P. cut its position in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 62.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,841 shares of the medical instruments supplier’s stock after selling 12,925 shares during the quarter. Point72 Asset Management L.P. owned about 0.14% of Mesa Laboratories worth $680,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in MLAB. Boone Capital Management LLC acquired a new position in shares of Mesa Laboratories during the 4th quarter worth approximately $6,712,000. Motley Fool Asset Management LLC boosted its position in Mesa Laboratories by 643.8% during the first quarter. Motley Fool Asset Management LLC now owns 64,776 shares of the medical instruments supplier’s stock worth $7,108,000 after purchasing an additional 56,067 shares during the period. Meros Investment Management LP bought a new position in Mesa Laboratories during the second quarter worth $2,456,000. Keeley Teton Advisors LLC acquired a new position in shares of Mesa Laboratories in the first quarter valued at $2,606,000. Finally, Dimensional Fund Advisors LP raised its position in shares of Mesa Laboratories by 7.1% in the second quarter. Dimensional Fund Advisors LP now owns 131,891 shares of the medical instruments supplier’s stock valued at $11,444,000 after purchasing an additional 8,722 shares during the period. 90.60% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Mesa Laboratories

In other Mesa Laboratories news, SVP Brian David Archbold sold 1,499 shares of the company’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $125.00, for a total transaction of $187,375.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 5.20% of the company’s stock.

Mesa Laboratories Price Performance

Shares of NASDAQ:MLAB opened at $133.58 on Friday. Mesa Laboratories, Inc. has a one year low of $82.86 and a one year high of $141.17. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.94 and a quick ratio of 1.37. The company has a market cap of $722.53 million, a price-to-earnings ratio of -2.83 and a beta of 0.85. The firm has a 50 day simple moving average of $124.84 and a 200 day simple moving average of $111.27.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings data on Monday, August 5th. The medical instruments supplier reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.55. The company had revenue of $58.17 million during the quarter, compared to the consensus estimate of $55.90 million. Mesa Laboratories had a positive return on equity of 18.95% and a negative net margin of 111.89%. Research analysts predict that Mesa Laboratories, Inc. will post 7.91 earnings per share for the current fiscal year.

Mesa Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Friday, November 29th will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.48%. The ex-dividend date of this dividend is Friday, November 29th. Mesa Laboratories’s payout ratio is -1.36%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on MLAB shares. Evercore ISI boosted their price objective on Mesa Laboratories from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Tuesday. Wells Fargo & Company began coverage on Mesa Laboratories in a report on Tuesday, August 27th. They issued an “underweight” rating and a $120.00 price objective on the stock.

About Mesa Laboratories

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.